{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-018161","form_type":"8-K","ticker":"INDP","cik":"0001857044","company_name":"Indaptus Therapeutics, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.915965+00:00","generated_at":"2026-06-02T13:20:58.861206+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Indaptus Therapeutics reports Q1 2024 results; R&D expense down 15% YoY","bullets":["R&D expenses $1.6M, down $0.3M or 15% vs Q1 2023; G&A expenses $2.4M, down 9%.","Initiated multi-dose cohort in Phase 1 trial of Decoy20 after positive preliminary results from second cohort.","Granted key patent in January 2024 to expand intellectual property portfolio.","Accepted for poster presentation at ASCO Annual Meeting on June 1, 2024, highlighting initial Phase 1 Decoy20 data."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-018161","json":"https://secwatch.observer/filing/0001493152-24-018161.json","markdown":"https://secwatch.observer/filing/0001493152-24-018161.md","text":"https://secwatch.observer/filing/0001493152-24-018161.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1857044/000149315224018161/0001493152-24-018161-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1857044/000149315224018161/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T13:20:58.861206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"adbe652d9d3d3096a5cad1d5445862bd5965847c","claim":"Indaptus Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 8, 2024, Indaptus Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1857044/000149315224018161/0001493152-24-018161-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}